KBC Group’s AMAG Pharmaceuticals AMAG Stock Holding History

KBC Group’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-52,184	Closed	-$400K	–	1306
2020 Q2	$400K	Sell	52,184 -12,382	-19%	-$94.7K	﹤0.01%	1068
2020 Q1	$399K	Sell	64,566 -95,514	-60%	-$842K	﹤0.01%	891
2019 Q4	$1.95M	Buy	160,080 +133,067	+493%	+$1.45M	0.01%	692
2019 Q3	$312K	Buy	+27,013	New	+$284K	﹤0.01%	1188
2019 Q1	–	Sell	-40,685	Closed	-$618K	–	1452
2018 Q4	$618K	Sell	40,685 -15,115	-27%	-$288K	0.01%	884
2018 Q3	$1.12M	Buy	+55,800	New	+$1.27M	0.01%	870
2017 Q3	–	Sell	-81,910	Closed	-$1.51M	–	1287
2017 Q2	$1.51M	Sell	81,910 -19,039	-19%	-$377K	0.01%	655
2017 Q1	$2.28M	Buy	+100,949	New	+$2.42M	0.02%	608
2016 Q1	–	Sell	-15,543	Closed	-$469K	–	1317
2015 Q4	$469K	Sell	15,543 -23,338	-60%	-$754K	0.01%	817
2015 Q3	$1.54M	Buy	+38,881	New	+$2.41M	0.03%	499

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KBC Group's AMAG Position: Q3 2020 in Review

KBC Group sold out of AMAG Pharmaceuticals (AMAG) in Q3 2020, closing a stake of 52,184 shares — an estimated $400K sold.

KBC Group first reported a position in AMAG in Q3 2015 and held it in 10 quarters. The position peaked at $2.28M in Q1 2017. 113 funds tracked by Wall St. Rank hold AMAG as of Q3 2020.

KBC Group reported no remaining AMAG Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
KBC Group sold 52,184 AMAG Pharmaceuticals shares in Q3 2020, an estimated $400K.
KBC Group first reported a position in AMAG Pharmaceuticals in Q3 2015 and held it in 10 quarters.
KBC Group's AMAG Pharmaceuticals position peaked at $2.28M in Q1 2017.
113 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2020.

Based on KBC Group's 13F filing for Q3 2020, filed 28 Oct 2020.